Table 2.

Oligonucleotides and plasmids used in this work.

Name	Sequence	Reference
Transposon generation
pMOD2	Source of Tn5 terminal ends, AmpR	Epicentre Biotechnology
pMOD2-tetT7	tetR pMOD2 derivative, containing outwards facing T7 promoters at both transposon ends	This work
Fw-Tet-pMOD2T7	CGCTAGTCTAGACCCTATAGTGAGTCGTATTAGCTCATGTACGGTAAGGAG	This work
Rev-Tet-pMOD2T7	CGCTAGGCATGCCCCTATAGTGAGTCGTATTAGCAAAACCCTCGGTCGGTCTGACCGGGGGTTTTGATTACATTACCTTCTGAAACATATGGC	This work
pMOD < MCS > Fw	ATTCAGGCTGCGCAACTGT	Epicentre Biotechnology
pMOD < MCS > Rev	GTCAGTGAGCGAGGAAGCGGAAG	Epicentre Biotechnology
TraDIS sequencing approach
5′ PCR enrichment primer sequence	AATGATACGGCGACCACCGAGATCTACACAATTCGAGCCAATATGCGAGAACACCCG	This work
3′ PCR enrichment primer sequence	AATGATACGGCGACCACCGAGATCTACACATGCAAGCTTGCCAACGACTACGCACTAGC	This work
5′ Sequencing primer sequence	ACCCGAGAAAATTCATCGATGATGGTTGAGATGTGTA	This work
3′ Sequencing primer sequence	ACCCGAGAAAATTCATCGATGATGGTTGAGATGTGTA	This work

^aRestriction sites are underlined.